A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin
Diabetes Therapy May 04, 2018
Witkowski M, et al. - Authors probed the efficacy and safety of once-weekly semaglutide vs other glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in patients with type 2 diabetes (T2D) inadequately controlled on basal insulin. Yielded results demonstrated that once-weekly semaglutide 1.0 mg as an add-on to basal insulin was possibly the most efficacious GLP-1 RA for reducing HbA1c and weight from baseline after 6 months of treatment. The efficacy of once-weekly semaglutide did not appear to be related to a marked increase in the incidence of gastrointestinal side-effects vs other GLP-1 RAs.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries